Non-Thermal Tumor Ablation Systems Market
完整報告名稱與涵蓋範圍
Non-Thermal Tumor Ablation Systems Market Size, Share & Trends Analysis Report, By Technology (Irreversible Electroporation Systems, Histotripsy and Focused Ultrasound Mechanical Ablation, Nanosecond Pulsed Electric Field Systems, Electrochemotherapy and Other Non-Thermal Modalities), By Application (Liver Tumors, Pancreatic Tumors, Prostate and Urologic Tumors, Kidney, Lung and Other Solid Tumors), By End User (Hospitals and Cancer Centers, Interventional Oncology and Radiology Centers), By Region, and Segment Forecasts, 2026-2035
報告摘要
The non-thermal tumor ablation systems market covers devices that destroy solid tumors without heat or cold, including irreversible electroporation, histotripsy and mechanical focused ultrasound, nanosecond pulsed electric field systems and electrochemotherapy, together with probes, consumables and treatment planning software, applied to liver, pancreatic, prostate, kidney, lung and other tumors. Thermal ablation modalities such as radiofrequency, microwave and cryoablation are excluded from revenue but analysed as the incumbent context.
Non-thermal approaches attract interest because they preserve vessels, ducts and nerves near the treatment zone, can address tumors adjacent to critical structures where heat is unsafe and, in the case of histotripsy, are entirely non-invasive and may stimulate immune responses. Regulatory clearances for histotripsy in liver tumors and expanding evidence for irreversible electroporation in pancreatic and prostate cancer have moved the category from investigational to commercial, and developers are pursuing indication expansion, combination with immunotherapy and integration with imaging for planning and verification. Reimbursement, capital cost, procedure time and comparative evidence against thermal ablation and surgery govern adoption.
North America leads commercial activity, with Europe, Japan and China following through regulatory approvals and hospital investment in interventional oncology. Competition involves interventional oncology device companies, focused ultrasound innovators and electroporation specialists, alongside thermal ablation leaders evaluating non-thermal extensions.
The InsightAce study provides US$ revenue forecasts for every technology, application and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-Thermal Tumor Ablation Systems Market Snapshot
Chapter 4. Global Non-Thermal Tumor Ablation Systems Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis
5.1. Technology & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
5.2.1. Irreversible Electroporation Systems
5.2.2. Histotripsy and Focused Ultrasound Mechanical Ablation
5.2.3. Nanosecond Pulsed Electric Field Systems
5.2.4. Electrochemotherapy and Other Non-Thermal Modalities
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. Liver Tumors
6.2.2. Pancreatic Tumors
6.2.3. Prostate and Urologic Tumors
6.2.4. Kidney, Lung and Other Solid Tumors
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals and Cancer Centers
7.2.2. Interventional Oncology and Radiology Centers
Chapter 8. Non-Thermal Tumor Ablation Systems Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. AngioDynamics, Inc.
10.2. HistoSonics, Inc.
10.3. Pulse Biosciences, Inc.
10.4. Galvanize Therapeutics, Inc.
10.5. IGEA S.p.A.
10.6. Mirai Medical
10.7. Medtronic plc
10.8. Johnson & Johnson MedTech (NeuWave Medical)
10.9. Boston Scientific Corporation
10.10. Varian (Siemens Healthineers AG) Interventional Solutions
10.11. Profound Medical Corp.
10.12. Insightec Ltd.
10.13. EDAP TMS S.A.
10.14. Theraclion SA
10.15. SonaCare Medical, LLC
圖表清單 List of Tables & Figures
Table 1. Global Non-Thermal Tumor Ablation Systems Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 1. Global Non-Thermal Tumor Ablation Systems Market Snapshot, 2026 & 2035
Table 2. Global Non-Thermal Tumor Ablation Systems Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global Non-Thermal Tumor Ablation Systems Market Share by Application, 2026 & 2035
Table 3. Global Non-Thermal Tumor Ablation Systems Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Non-Thermal Ablation Technology Comparison: Mechanism, Invasiveness and Tissue Selectivity
Table 4. North America Non-Thermal Tumor Ablation Systems Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Indication Expansion Roadmap and Regulatory Status by Modality, 2026
Table 5. Europe Non-Thermal Tumor Ablation Systems Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Non-Thermal Tumor Ablation Systems Growth Opportunity Analysis
Table 6. Asia Pacific Non-Thermal Tumor Ablation Systems Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Clinical Evidence and Reimbursement Milestones Driving Adoption
Table 7. Latin America and Middle East & Africa Non-Thermal Tumor Ablation Systems Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Non-Thermal Tumor Ablation Systems Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們